<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02027779</url>
  </required_header>
  <id_info>
    <org_study_id>GreenGene™ F_E_P3</org_study_id>
    <nct_id>NCT02027779</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A</brief_title>
  <official_title>An Open Label Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Atlantic Research Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study primarily will address the safety and secondarily will assess efficacy of&#xD;
      GreenGene™ F in subjects with severe hemophilia A previously treated ≥50 exposure days with a&#xD;
      GreenGene™ F, and without presence inhibitor to FVIII (Factor VIII).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with development of inhibitors</measure>
    <time_frame>every 3 months, up to 18 months</time_frame>
    <description>Development of neutralizing antibodies (inhibitors) will be followed during the regular visits, average of 3 months.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Prophylaxis safety and efficacy substudy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding during prophylaxis over ≥ 50 additional exposure days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>On-demand safety and efficacy substudy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding in a minimum of 10 on demand treated subjects during additional 50 exposure days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GreenGene™ F</intervention_name>
    <description>Prophylaxis safety and efficacy substudy:&#xD;
intra venous infusion, 30 ± 10 IU/kg infusions 3 times per week with dose escalation to 45 ± 10 IU/kg if appropriate, for 50 exposure days</description>
    <arm_group_label>Prophylaxis safety and efficacy substudy</arm_group_label>
    <other_name>GreenGeneF</other_name>
    <other_name>GreenGene F</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GreenGene™ F</intervention_name>
    <description>On-demand safety and efficacy substudy:&#xD;
minor bleed = 20 ± 10 IU/kg moderate bleed = 30 ± 10 IU/kg major bleed = 30 - 50 IU/kg</description>
    <arm_group_label>On-demand safety and efficacy substudy</arm_group_label>
    <other_name>GreenGeneF</other_name>
    <other_name>GreenGene F</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must have participated in the &quot;GreenGene™ F_P3&quot;, (with Eudra CT number&#xD;
             2012-001445-40) or a pediatric study with GreenGene™ F&#xD;
&#xD;
          2. Have ≥50 previous exposure days to GreenGene™ F, as documented in the subject's&#xD;
             medical records.&#xD;
&#xD;
          3. Negative assays for FVIII inhibitor at inclusion (&lt;0.6BU Nijmegen assay), i.e. at the&#xD;
             end of study &quot;GreenGene™ F_P3&quot; for patients entering into this extension study&#xD;
             immediately after finishing the previous phase III study.&#xD;
&#xD;
          4. Normal liver and kidney function&#xD;
&#xD;
          5. Platelet count ≥ 100,000㎕&#xD;
&#xD;
          6. Normal prothrombin time or International Normalized Ratio (INR) &lt; 1.5&#xD;
&#xD;
          7. Subjects receiving therapy for human immunodeficiency virus (HIV) or hepatitis must be&#xD;
             on a stable treatment regimen&#xD;
&#xD;
          8. Subjects must be able to withhold FVIII infusions for approximately 72 h prior to each&#xD;
             inhibitor assay&#xD;
&#xD;
          9. Absolute CD4 lymphocyte cell count ≥ 200㎕&#xD;
&#xD;
         10. Signed the written informed consent form or informed consent was obtained from the&#xD;
             subject's legal guardian&#xD;
&#xD;
         11. Females must not be lactating or pregnant at screening or Baseline (as documented by a&#xD;
             negative beta-human chorionic gonadotropin [β-hCG] test with a minimum sensitivity of&#xD;
             25 IU/L or equivalent units of β-hCG). A test was obtained more than 72 hours before&#xD;
             the first dose of study drug&#xD;
&#xD;
         12. All females will be considered to be of childbearing potential unless they are&#xD;
             appropriate age group and without other known or suspected cause) or have been&#xD;
             sterilized surgically (i.e. bilateral tubal ligation, total hysterectomy or bilateral&#xD;
             oophorectomy, all with surgery at least one month before dosing)&#xD;
&#xD;
         13. Willing and able to comply with all aspects of the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence at Screening of FVIII inhibitor ≥ 0.6 BU as tested with the Nijmegen&#xD;
             modification of the Bethesda assay.&#xD;
&#xD;
          2. Laboratory or clinical evidence of portal vein hypertension including, but not limited&#xD;
             to, an INR &gt; 1.4, the presence of splenomegaly and/or spider angiomata of physical&#xD;
             examination and/or a history of esophageal hemorrhage or documented esophageal varices&#xD;
&#xD;
          3. Uncontrolled hypertension (diastolic blood pressure &gt;100 mm Hg)&#xD;
&#xD;
          4. Hemoglobin &lt; 10 g/dL&#xD;
&#xD;
          5. Severe renal dysfunction (creatinine &gt; 2x upper limit of normal [ULN], total bilirubin&#xD;
             &gt; 2x the ULN)&#xD;
&#xD;
          6. Liver disease (alanine aminotransferase [ALT], aspartate aminotransferase [AST] &gt; 3x&#xD;
             the ULN)&#xD;
&#xD;
          7. History of diabetes or other metabolic disease&#xD;
&#xD;
          8. History of hypersensitivity or serious adverse reaction to recombinant or&#xD;
             plasma-derived FVIII concentrates&#xD;
&#xD;
          9. History of pretreatment prior to the administration of FVIII products (e.g.,&#xD;
             antihistamines)&#xD;
&#xD;
         10. Regular use of antifibrinolytics or medications affecting platelet function&#xD;
&#xD;
         11. Hypersensitivity to hamster- or mouse derived proteins&#xD;
&#xD;
         12. Blood transfusions within 30 days of enrollment into the study&#xD;
&#xD;
         13. Current participation in another investigational drug or device study, or participated&#xD;
             in a clinical study involving an investigational drug or device within 30 days of&#xD;
             enrollment into the study&#xD;
&#xD;
         14. Unable or unwilling to cooperate with study procedures&#xD;
&#xD;
         15. Females who are pregnant (positive β-hCG test) or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chang Hee Lee, M.D.</last_name>
    <phone>+82 31 260 9729</phone>
    <email>chleedr@greencross.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kevin Wait</last_name>
    <phone>+1 540 649 5490</phone>
    <email>kwait@atlanticresearchgroup.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryce Warren</last_name>
      <phone>501-364-4003</phone>
      <email>WarrenBryceA@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Kimo Stine, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center - Hemophilia Treatment Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Murray</last_name>
      <phone>718-470-7380</phone>
      <email>Pmurray1@nshs.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Patriarca</last_name>
      <phone>718 470 7380</phone>
      <email>lpatriar@nshs.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Lipton, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>January 2, 2014</study_first_submitted>
  <study_first_submitted_qc>January 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2014</study_first_posted>
  <last_update_submitted>January 3, 2014</last_update_submitted>
  <last_update_submitted_qc>January 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GreenGene™ F, Previously Treated Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

